Evidence map›Paper›PMID 36577856›Full record

ArticleBone marrow transplantation2023

Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.

Roland B Walter, Brenda M Sandmaier, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí, Masumi U Oshima, Gary Schoch, Chris Davis, H Joachim Deeg, Rainer Storb

Open access · greenAbstract read
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. New age HCT conditioning regimens: what works and why?Hematology. American Society of Hematology. Education Program · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Roland B WalterFred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.ORCID 0000-0002-9268-3341
Brenda M SandmaierFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-9767-9739
Megan OthusFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-8176-6371
Corentin OrvainFred Hutchinson Cancer Center, Seattle, WA, USA.
Eduardo Rodríguez-ArbolíFred Hutchinson Cancer Center, Seattle, WA, USA.
Masumi U OshimaFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-2277-1976
Gary SchochFred Hutchinson Cancer Center, Seattle, WA, USA.
Chris DavisFred Hutchinson Cancer Center, Seattle, WA, USA.
H Joachim DeegFred Hutchinson Cancer Center, Seattle, WA, USA.
Rainer StorbFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-9343-4099
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

Reduced intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning regimens have expanded use of allogeneic hematopoietic cell transplantation (HCT) in AML to include older and medically less-fit patients, but relative efficacies and toxicities remain poorly defined. Here, we analyzed outcomes from 343 adults transplanted in remission after RIC (n = 137) or NMA (n = 206) conditioning between 2006 and 2021. The characteristics of RIC and NMA HCT patients were similar except that RIC patients were younger and their time between most recent remission achievement and allografting was shorter. There were no significant differences in relapse risk, relapse-free survival (RFS), overall survival (OS), and non-relapse mortality (NRM) between RIC and NMA HCT patients, both overall (relapse: hazard ratio [HR] = 0.80, P = 0.27; RFS: HR = 0.93, P = 0.61; OS: HR = 0.93, P = 0.66; NRM: HR = 1.13, P = 0.59) and when patients were stratified by pre-HCT measurable residual disease (MRD) status. After multivariable adjustment, there was no statistically significant association between conditioning intensity and relapse (HR = 0.69, P = 0.088), RFS (HR = 0.86, P = 0.37), OS (HR = 0.89, P = 0.49), or NRM (HR = 1.37, P = 0.19). In this non-randomized cohort of adults undergoing allografting for AML in first or second remission at our center, we could not detect statistically significant differences in outcomes between those assigned to RIC and those assigned to NMA conditioning.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultHumansRecurrenceRetrospective StudiesTransplantation ConditioningTransplantation, Homologous

Identifiers

PMID36577856
PMCPMC10170527
OpenAlexW4313379935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.